Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
3
75%
Ph early_phase_1
1
25%

Phase Distribution

4

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Early Phase 1First-in-human
1(25.0%)
Phase 1Safety & dosage
3(75.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Active(2)
Completed(2)

Detailed Status

Not yet recruiting2
Completed2

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 1

Trials by Phase

Early Phase 11 (25.0%)
Phase 13 (75.0%)

Trials by Status

not_yet_recruiting250%
completed250%

Recent Activity

0 active trials
Showing 4 of 4
not_yet_recruitingphase_1

Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial for First-line Treatment of Hepatocellular Carcinoma

NCT06364787
not_yet_recruitingearly_phase_1

Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial of Hepatocellular Carcinoma Resistant to PD-1 Monoclonal Antibody

NCT06364800
completedphase_1

Safety and Efficiency of γδ T Cell Against Breast Cancer

NCT03183206
completedphase_1

Safety and Efficiency of γδ T Cell Against Hepatocellular Liver Cancer

NCT02425735

Clinical Trials (4)

Showing 4 of 4 trials
NCT06364787Phase 1

Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial for First-line Treatment of Hepatocellular Carcinoma

Not Yet Recruiting
NCT06364800Early Phase 1

Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial of Hepatocellular Carcinoma Resistant to PD-1 Monoclonal Antibody

Not Yet Recruiting
NCT03183206Phase 1

Safety and Efficiency of γδ T Cell Against Breast Cancer

Completed
NCT02425735Phase 1

Safety and Efficiency of γδ T Cell Against Hepatocellular Liver Cancer

Completed

All 4 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
4